Your browser doesn't support javascript.
loading
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.
Yang, Da-Wei; Ju, Min-Jie; Wang, Hao; Jia, Yi-Chen; Wang, Xiao-Dan; Fang, Hao; Fan, Jia.
Affiliation
  • Yang DW; Department of Pulmonary and Critical Care Medicine, Shanghai Engineering Research Center of Internet of Things for Respiratory Medicine, Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Institute of Infectious Disease and Biosecurity, Zhongshan Hospital Fudan University, Shanghai, C
  • Ju MJ; Department of Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China.
  • Wang H; Department of Thoracic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
  • Jia YC; Department of Urology, Zhongshan Hospital Fudan University, Shanghai, China.
  • Wang XD; Department of Pulmonary and Critical Care Medicine, Shanghai Engineering Research Center of Internet of Things for Respiratory Medicine, Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Institute of Infectious Disease and Biosecurity, Zhongshan Hospital Fudan University, Shanghai, C
  • Fang H; Department of Anesthesiology, Zhongshan Hospital Fudan University, Shanghai, China.
  • Fan J; Department of Anesthesiology, Minhang Hospital, Fudan University, Shanghai, China.
J Clin Lab Anal ; 37(7): e24880, 2023 Apr.
Article in En | MEDLINE | ID: mdl-37088868
ABSTRACT

BACKGROUND:

The pandemic the coronavirus disease 2019 (COVID-19) has created a global health crisis. Although Paxlovid is recommended for the early-stage treatment of mild-to-moderate COVID-19 in patients at increased risk of progression to severe COVID-19, more and more cases are reported a COVID-19 rebound after Paxlovid treatment. Currently, information on the additional treatment for COVID-19 rebound following Paxlovid treatment is limited. CASE REPORT Here, we present four cases with COVID-19 who were mild on admission. All cases experienced a COVID-19 rebound and progressed to severe COVID-19, following treatment with Paxlovid (300 mg of nirmatrelvir with 100 mg ritonavir, twice daily for 5 days). After being treated with proxalutamide (300 mg/day), all cases finally turned real-time reverse transcription polymerase chain reaction (RT-PCR) negative.

CONCLUSION:

Our cases suggested that proxalutamide might be an effective remedial treatment option for patients experiencing a COVID-19 rebound after Paxlovid treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: J Clin Lab Anal Journal subject: TECNICAS E PROCEDIMENTOS DE LABORATORIO Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: J Clin Lab Anal Journal subject: TECNICAS E PROCEDIMENTOS DE LABORATORIO Year: 2023 Document type: Article